[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615554":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":33,"centralContacts":38,"locations":44,"responsibleParty":62,"collaborators":23,"id":64,"slug":23,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":23,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":23,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":23,"overallStatus":46,"whyStopped":23,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"The University of Texas Medical Branch, Galveston","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Lidocaine (50 mg bilaterally)","EXPERIMENTAL","The participants will receive 50 mg of lidocaine.",[13],"Drug: Lidocaine",{"label":15,"type":10,"description":16,"interventionNames":17},"Lidocaine (50 mg) + Dexamethasone (10 mg bilaterally)","The participant will receive Lidocaine (50 mg) + Dexamethasone (10 mg bilaterally)",[18],"Drug: Lidocaine and Dexamethasone",{"label":20,"type":21,"description":22,"interventionNames":23},"No injection (Control group)","NO_INTERVENTION","The participant will not receive an injection.",null,[25,29],{"type":26,"name":27,"description":11,"armGroupLabels":28,"otherNames":23},"DRUG","Lidocaine",[9],{"type":26,"name":30,"description":31,"armGroupLabels":32,"otherNames":23},"Lidocaine and Dexamethasone","The participants will receive 50 mg of lidocaine and 10 mg of dexamethasone one after the other.",[15],[34],{"name":35,"affiliation":36,"role":37},"Kan Peter, MD","University of Texas Medical Branch, Galveston","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":23,"email":43},"Matias Costa","CONTACT","409-772-1011","mlcosta@utmb.edu",[45],{"facility":36,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Galveston","Texas","77555-0158","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-94.7977,29.30135,{"lat":56,"lon":55},[59,60],{"name":40,"role":41,"phone":42,"phoneExt":23,"email":43},{"name":61,"role":37,"phone":23,"phoneExt":23,"email":23},"Peter Kan, MD",{"type":63,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100615554",false,"NCT07294118","Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage","Endovascular Infusion of Lidocaine and Steroids in the Middle Meningeal Artery for Pain Management in Spontaneous Subarachnoid Hemorrhage Patients","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosed with aneurysmal SAH, Hunt and Hess Grades 1-2.\n* Consent to study procedures and follow-up evaluations.\n\nExclusion Criteria:\n\n* Known allergies to lidocaine or steroids.\n* Arteriovenous malformations.\n* Dural Arteriovenous Fistulas.\n* Other significant intracranial pathologies.\n* Hemodynamic instability preventing safe intervention.\n* Previous MMA interventions.\n* Previous craniotomies or need for craniotomy.\n* Need for external ventricular drain.","ALL","18 Years","100 Years",{"count":74,"type":75},15,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The goal of this clinical trial is to learn if an infusion of lidocaine, with or without steroids, into the middle meningeal artery (MMA) helps relieve severe headaches in patients with spontaneous subarachnoid hemorrhage (SAH). It will also study the safety of this treatment.",[81,82,83,84],"Subarachnoid Hemorrhage, Aneurysmal","Headache","Opiate Dependence","Opioid Use","2026-01-07",{"date":87,"type":88},"2026-01-09","ACTUAL",{"date":90,"type":88},"2026-01-02",{"date":92,"type":75},"2027-08",{"name":5,"class":6},1]